{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"180.0","upperLimit":"553.0","value":"413.0"},{"groupId":"OG001","lowerLimit":"35.0","upperLimit":"285.0","value":"155.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Duration of response (in number of days) was calculated from the first time the response was observed to time of relapse or last time point in the study. Kaplan-Meier estimate for complete response is shown.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m\\^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.","id":"OG000","title":"Phase 2 Dose Confirmation"},{"description":"Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m\\^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.","id":"OG001","title":"Phase 2 Fixed-Dose Combination"}],"paramType":"MEDIAN","populationDescription":"The efficacy population includes all participants in Phase 2 who received at least one dose of investigational product.","reportingStatus":"POSTED","timeFrame":"Up to approximately 29 months","title":"Duration of Complete Response in Phase 2 - Kaplan-Meier Estimate","type":"SECONDARY","unitOfMeasure":"days"}